 3000 women aged within the age range of 25-45 years old will be recruited; 250-300 women per country. These women will be identified by means of screening registry lists or screening clinical visits. Eligible women will receive a study questionnaire on the HPV vaccine. Additionally, and independently of participating in the study questionnaire, those who accept will get 3 HPV vaccine doses. Depending on country preferences, either Cervarix Glaxosmithkline Biologicals, S.A. at month 0, 1 and 6 or Gardasil Sanofi Pasteur MSD SNC at month 0, 2 and 6, will be administered. 